Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by JACOBSEN, S.
Right arrow Articles by DANNESKIOLD–SAMSØE, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JACOBSEN, S.
Right arrow Articles by DANNESKIOLD–SAMSØE, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 British Society for Rheumatology

other

PRIMARY FIBROMYALGIA: CLINICAL PARAMETERS IN RELATION TO SERUM PROCOLLAGEN TYPE III AMINOTERMINAL PEPTIDE

S. JACOBSEN*,, L. T. JENSEN{dagger}, M. FOLDAGER* and B. DANNESKIOLD–SAMSØE*

*Department of Rheumatology, Frederiksberg Hospital Denmark
{dagger}Department of Rheumatology, Hvidovre Hospital Denmark

Correspondence to: Correspondence to Dr S. Jacobsen, Department of Rheumatology, Frederiksberg Hospital Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark

Serum concentrations of procollagen type III aminoterminal peptide have previously been reported to be low in some patients with primary fibromyalgia and the aim of this study was to determine if such patients differ clinically from primary fibromyalgia patients with normal levels of procollagen type III aminoterminal peptide

Subjective symptoms, tender points and dynamic muscle strength in 45 women with primary fibromyalgia were related to serum concentrations of procollagen type III aminoterminal peptide

Patients with low serum concentrations of procollagen type III aminoterminal peptide had more symptoms, a higher frequency of tender points and lesser quality of sleep compared to patients with normal serum concentrations of procollagen type III aminoterminal peptide (P≤0·05). They also had a lower dynamic muscle strength (P0·0005)

We conclude that the serum concentrations of procollagen type III aminoterminal peptide of primary fibromyalgia patients are connected to the disease impact

KEY WORDS: Primary fibromyalgia, Fibrositis, Procollagen type III aminoterminal peptide, Muscle function, Sleep disturbance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. T. Gronemann, S. Ribel-Madsen, E. M. Bartels, B. Danneskiold-Samsoe, and H. Bliddal
Collagen and muscle pathology in fibromyalgia patients
Rheumatology, January 1, 2004; 43(1): 27 - 31.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.